New technology allows for faster drug development thanks to the small particles.
The basis of many modern medicines is microorganisms grown in laboratory. Many microorganisms are smaller, more fragile, and evolve too quickly in nature than can be grown in laboratories. In culture, microbes behave differently to those from nature and have a limited ability to perform chemical reactions that are essential for drug discovery and product development.
Biosortia Pharmaceuticals discovered a way to get the hidden chemistry in microorganisms, and extract small molecules directly from nature.
Biosortia makes use of its technology to extract microbiomes from the soil in both quantity and quality. This is called microbiome mining. Biosortia is adding microbiomes to its growing collection of patentable natural molecules activity and derivatives. These can be used in a variety of industries including pharmaceutical, cosmetic, agricultural and agricultural to solve problems or create products.
“Microbes are and have always been chemical researchers and factories of life,”Ross Youngs, CEO and founder of Biosortia.
Biosortia is capable of recovering active microbiomes. “massive opportunities to explore the unknown,”In a LinkedIn post, he said this.
Biosortia’s approach to microbiome mining has many advantages
– More options Biosortia has unprecedented access to molecules previously unknown that could be used in a variety of industries. The company can also provide a genome roadmap that can accompany data on the activity.
– More efficiency.Biosortia can access material from the microbiome within days as opposed to the many years required by other researchers. Biosortia technology is also significantly cheaper than traditional methods for microorganism growth.
More success.Small molecules that are accessed directly through the microbiome will be more successful in clinical development than those grown in a laboratory, because they have already reached their full potential in nature.
Biorsortia continues its expansion and has obtained four patents so far, in addition to a pending contract from the Department of Homeland Security. The American Chemical Society awarded Biorsortia an Editor’s Choice Award for its science team publication technology.
Visit www.amazon.com for more information fundable.com/biosortia.
